Company Profile
BioMS Medical is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of Multiple Sclerosis (MS).
BioMS Medical has obtained an exclusive worldwide license to a proprietary technology developed at the MS Patient Care and Research Clinic at the University of Alberta for the treatment of MS. The technology, dirucotide (MBP8298), is a synthetic myelin basic protein peptide comprised of 17 amino acids which is intravenously injected (every six months) into MS patients as a therapeutic treatment.
BioMS is currently conducting three late-stage clinical trials and one open-label trial for dirucotide (MBP8298):
 |
A pivotal phase III trial in Canada and Western Europe evaluating dirucotide (MBP8298) for the treatment of Secondary Progressive Multiple Sclerosis (SPMS). The trial is a randomized, double-blind study and has completed full recruitment of 611 patients at 47 trial sites in 10 countries. |
 |
An open-label, follow-on trial to MAESTRO-01. |
 |
A pivotal phase III U.S. trial evaluating dirucotide (MBP8298) for the treatment of Secondary Progressive Multiple Sclerosis (SPMS). The trial is a randomized, double-blind study and has completed full recruitment of approximately 510 patients at 68 sites. |
 |
A phase II trial evaluating dirucotide (MBP8298) for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The trial is a randomized, double-blind study and has completed full recruitment of 218 patients at 24 sites in 6 countries. |
BioMS Medical is a publicly traded company on the Toronto Stock Exchange (TSX: MS).